This article reviews the information available to assist pharmacokineticists in the prediction
of metabolic drug interactions. Significant advances in this area have been made in the last …

A number of therapeutic drugs with different structures and mechanisms of action have been
reported to undergo metabolic activation by Phase I or Phase II drug-metabolizing enzymes …

Increased atherosclerosis risk in hyperlipidemic patients may be a result of the enhanced
oxidizability of their plasma lipoproteins. We have previously shown that …

Featuring more than 4100 references, Drug-Induced Liver Disease is an invaluable
reference for gastroenterologists, hepatologists, family physicians, internists, pathologists …

In a definitive review of 1987, Kaspersen and van Boeckel1 presented a concise account of
the chemical synthesis of glucuronide and sulfate conjugates of xenobiotics. At that time, O …

Telmisartan 1-O-acylglucuronide, the principal metabolite of telmisartan in humans, was
characterized in terms of chemical stability and the structure of its isomerization products …

A new type of quadrupole linear ion trap mass spectrometer, Q TRAP™ LC/MS/MS system
(Q TRAP™), was evaluated for its performance in two studies: firstly, the in vitro metabolism …

Gemfibrozil-1-O-β-glucuronide (GEM-1-O-gluc), a major metabolite of the antihyperlipidemic
drug gemfibrozil, is a mechanism-based inhibitor of P450 2C8 in vitro, and this irreversible …

Acyl glucuronides are a unique class of electrophilic metabolites, capable of non-enzymatic
reactions including acylation and/or glycation of endogenous macromolecules, hydrolysis to …

Gemfibrozil (GEM), a lipid regulator, is a fibric acid derivative widely used in the treatment of
hyperlipidemia. It has been reported that GEM can induce acute liver injury in the course of …